Healthcare Roundup—Legislators call for price transparency for insulin 

Washington, D.C. National Capitol Building
The Congressional Diabetes Caucus has offered 11 policy recommendations to bring down insulin prices, plus more healthcare headlines. (Getty/tupungato)

Report: Value-based contracts, transparency could bring down insulin prices 

The Congressional Diabetes Caucus issued a report on the rising cost of insulin and identified 11 policy recommendations that could bring down prices. 

The market for insulin is not especially competitive, the legislators found, with just three drug companies producing it and three wholesalers controlling 85% of distribution. As such, moving toward more value-based contracts and promoting price transparency are two crucial solutions to drive down costs. 

The report also suggests allowing generic drugmakers to produce older, off-patient insulin formulas and capping out-of-pocket costs for patients who have chronic diseases like diabetes.

Conference

13th Partnering with ACOS & IDNS Summit

This two-day summit taking place on June 10–11, 2019, offers a unique opportunity to have invaluable face-to-face time with key executives from various ACOs and IDNs from the entire nation – totaling over 3.5 million patients served in 2018. Exclusively at this summit, attendees are provided with inside information and data from case studies on how to structure an ACO/IDN pitch, allowing them to gain the tools to position their organization as a “strategic partner” to ACOs and IDNs, rather than a merely a “vendor.”

“Many cannot live without [insulin], but countless patient struggle to afford it,” Reps. Tom Reed, R-N.Y., and Diana DeGette, D-Colo., the caucus’ co-chairs, said. “As their out-of-pocket costs continue to rise, the current system is unfairly putting insulin out of reach, placing millions of lives at risk.” (Announcement

VA moves ahead with deadly experiments on dogs despite backlash from Congress, veterans 

Medical researchers at the Department of Veterans Affairs are pushing on with fatal experiments on dogs, despite controversy over the practice, documents obtained by USA Today show. 

The department was conducting lethal research on the dogs that it says could lead to crucial breakthroughs in spine and respiratory care. However, some veterans advocacy organizations decried the studies, and Congress had implemented stiff restrictions. 

USA Today’s investigation found that nine experiments on dogs are active within the VA, with more potentially planned. The VA maintains that the research is “ethically sound.” (USA Today)

Mayo Clinic asks congressional candidate to remove it from political ads 

Mayo Clinic has asked a Republican candidate for Congress in Minnesota to stop using its name in political ads. 

Jim Hagedorn and the National Republican Congressional Committee aired an ad that notes Mayo topped U.S. News & World Report’s list of the country’s best hospitals, before warning that Democratic opponent Dan Feehan would “blow up” by pushing for universal healthcare coverage. 

Mayo Clinic said in a statement that it doesn’t work with campaigns. 

“Mayo Clinic does not endorse candidates nor does the organization coordinate with political campaigns on activities or endorsements,” the healthcare system said. (Fox 47)

Suggested Articles

Following the rollout of the ACA, emergency department visits and hospitalizations by uninsured patients have decreased, a new study shows.

As a safe nonpharmacological form of treatment, physical therapy (PT) could become a risk-free alternative to opioid-based pain management regimens.

President Donald Trump's proposed federal budget calls for $291 million for the Ending the HIV Epidemic plan in fiscal year 2020.